Let's get to Jim and stop trading. One of my favorite executives is David Ricks from Eli Liy. He came on after that last trial and that was the uh a trial for weight loss obviously August 7225.He said look our stocks shouldn't be down that much. I mean there's a lot more things in the pipeline. He then bought 1,632 shares at 645 uh August 12th.He said saying basically look we're we're not bad. Well, of course, the new tri another trial came out today, August 26. Same kind, the misinformation thing is so leg ...

Core Insights - Hims & Hers is experiencing rapid revenue growth but is currently facing a legal battle that poses risks to its future performance [1][4] - The company's stock has seen a significant decline of 17% this week and is down 25% from its all-time highs, despite a remarkable 400% increase over the past five years [1][2] Financial Performance - In Q2 2025, Hims & Hers reported a 73% year-over-year revenue growth, exceeding $500 million, driven by a 30% increase in total subscribers and a 30% rise in spending per active subscriber [2] - The company has achieved $2 billion in trailing revenue, marking an increase of over 1,000% in the last five years, solidifying its position as a leading telehealth provider [6] Legal Challenges - Hims & Hers is embroiled in a legal dispute with Novo Nordisk, stemming from allegations of selling knockoff weight loss drugs after a partnership ended due to disagreements [3][4] - The company is accused of illegally selling patented weight loss drugs at a discount now that the shortage has resolved, raising concerns among investors about the potential impact on future revenue and profitability [3][4] Market Position - Hims & Hers has made significant market share gains in the telehealth sector, particularly in the online provision of drugs and medical treatments [6] - Despite its strong growth trajectory, the ongoing legal issues may deter potential investors from buying the stock at its current dip [7][8]

Your next guest warned you about a red-hot stock a few months ago, but only if you listened. And then on Monday, Hims and Hers crashed, tanking 30% after Novo Nordisk accused the company of deceptive marketing. Hims and Hers, of course, denies it.You guys talked about it in the one:00 show, Kelly. But let's find out what Herb Greenberg may have seen that others didn't. Herb, of course, a CNBC contributor.He raised a red flag on Hims back in February and he joins us now on the the Herb hotline as we're now g ...